These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 7903202

  • 1. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH.
    Cancer Res; 1994 Jan 01; 54(1):152-8. PubMed ID: 7903202
    [Abstract] [Full Text] [Related]

  • 2. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM.
    Cancer Res; 1991 Oct 01; 51(19):5275-83. PubMed ID: 1717144
    [Abstract] [Full Text] [Related]

  • 4. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP.
    Cancer Res; 1993 Oct 15; 53(20):4866-73. PubMed ID: 8104687
    [Abstract] [Full Text] [Related]

  • 5. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA, Padmanabhan R, Hwang J, Gottesman MM, Pastan I.
    J Cell Physiol; 1993 May 15; 155(2):414-25. PubMed ID: 8097746
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 7. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
    Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH.
    Cancer Res; 1992 Nov 15; 52(22):6175-81. PubMed ID: 1358431
    [Abstract] [Full Text] [Related]

  • 8. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS, Danks MK, Schmidt CA, Beck WT.
    Cancer Res; 1989 May 01; 49(9):2422-6. PubMed ID: 2539902
    [Abstract] [Full Text] [Related]

  • 9. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC.
    Cancer Res; 1988 Nov 01; 48(21):5956-64. PubMed ID: 2844393
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G, Lorico A, Sartorelli AC.
    Cancer Res; 1993 Nov 15; 53(22):5487-93. PubMed ID: 8106148
    [Abstract] [Full Text] [Related]

  • 12. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G, Lorico A, Sartorelli AC.
    Cancer Res; 1992 May 15; 52(10):2782-90. PubMed ID: 1316227
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y.
    Cancer Commun; 1989 May 15; 1(4):217-24. PubMed ID: 2576973
    [Abstract] [Full Text] [Related]

  • 15. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y, Takano H, Nagao S, Fojo T.
    Jpn J Cancer Res; 2001 Sep 15; 92(9):968-74. PubMed ID: 11572765
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Sep 15; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC.
    Mol Pharmacol; 1994 Jul 15; 46(1):58-66. PubMed ID: 8058057
    [Abstract] [Full Text] [Related]

  • 20. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S, Austin CA, Fisher LM.
    Anticancer Drug Des; 1990 Feb 15; 5(1):149-57. PubMed ID: 2156515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.